Background Uveal melanoma (UM) represents the most common primary intra-ocular
malignancy in adults. Up to 50% of the patients develop distant metastases within 10 years …

Background To date, no systemic therapy, including immunotherapy, exists to improve
clinical outcomes in metastatic uveal melanoma (UM) patients. To understand the role of …

Introduction Uveal melanoma (UM) is the most common intraocular cancer and represents a
discrete subtype of melanoma. Metastatic disease, which occurs in half of patients, has a …

Simple Summary Uveal melanoma (UM) is a rare aggressive eye cancer. Although
treatment of the eye tumour is successful, about 50% of UM patients develop a relapse of …

The low response rates to immunotherapy in uveal melanoma (UM) sharply contrast with
reputable response rates in cutaneous melanoma (CM) patients. To characterize the …

Tumor‐infiltrating immune cells are capable of effective cancer surveillance, and their
abundance is linked to better prognosis in numerous tumor types. However, in uveal …

Background The profound disparity in response to immune checkpoint blockade (ICB) by
cutaneous melanoma (CM) and uveal melanoma (UM) patients is not well understood …

Current treatments for metastatic uveal melanoma (mUM) are limited and rarely prolong
patient survival. Immunotherapy trials for mUM are few and to date have demonstrated only …

Uveal melanoma is an intraocular malignancy that, depending on its size and genetic make-
up, may lead to metastases in up to 50% of cases. Currently, no therapy has been proven to …

Metastatic uveal melanoma (UM) is a poor prognosis malignancy. Immunotherapy is
commonly employed, despite the low activity, considering the lack of other effective systemic …